HepaTx Corporation (YC S18)

A New Alternative To Liver Transplants

https://wefunder.com/hepatx

Total raised on Wefunder: 123161

Total investors: 69

Quick facts

  • Breakthrough therapeutic Hx-001 is designed to regenerate liver and reduces the need for transplants
  • Addressing $20B+ liver disease crisis affecting 1/5 adults, 70% cheaper than transplants
  • Preclinical studies show encouraging signs of reduced liver damage, inflammation, and fibrosis
  • Prestigious Mayo Clinic license agreement brings expertise to reduce manufacturing and clinical risk
  • Raising $1.2M to unlock manufacturing readiness and studies to enter human trials within 24 months
  • Proprietary ProteoTrack diagnostic system offers a future second revenue stream
  • Backed by YC and Stanford StartX, raised > $4.2M with ~$700K in grants
  • Deeply experienced biotech leadership and scientific advisors

Team profiles

Featured investor profiles

Invest in HepaTx Corporation (YC S18)

A New Alternative To Liver Transplants

$358,850

raised from 69+ investors
INVESTMENT TERMS
Future Equity
 $17.5M  $15M post-money valuation cap
Early Bird Bonus: The first $300K of investments will be in a SAFE with a $15M valuation cap

What Investors Say

What People Say